Uniqure N.V. insider trading
Every open-market purchase and sale by Uniqure N.V.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Uniqure N.V.’s insiders pay?
From January 3, 2018 to June 30, 2026, 24 insiders reported 0 open-market purchases and 148 sales not made under a pre-set plan in Uniqure N.V. After sales, the shares moved −2.1% against the index over 12 months (a negative figure means selling was the right call).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Klemt Christian | Chief Financial Officer | 0 | — | — | 22 | −15.2% (19) | March 6, 2026 |
| Kapusta Matthew C | CEO, Managing Director | 0 | — | — | 16 | −3.0% (13) | March 6, 2026 |
| Kuta Alexander Edward III | Executive VP, Operations | 0 | — | — | 12 | −46.4% (12) | March 9, 2023 |
| Gut Robert | Chief Medical Officer | 0 | — | — | 11 | −17.2% (10) | June 24, 2025 |
| Kaye Jack | Director | 0 | — | — | 9 | +24.8% (7) | June 12, 2026 |
| Balachandran Madhavan | Director | 0 | — | — | 8 | +12.7% (6) | June 12, 2026 |
| Springhorn Jeremy P. | Director | 0 | — | — | 8 | +12.7% (6) | June 12, 2026 |
| Caloz Pierre | Chief Operating Officer | 0 | — | — | 7 | −58.2% (6) | June 20, 2024 |
| Meek David D. | Director | 0 | — | — | 7 | +5.9% (5) | June 12, 2026 |
| Soteropoulos Paula | Director | 0 | — | — | 7 | −6.7% (6) | June 17, 2024 |
| Dolmetsch Ricardo | President, R&D | 0 | — | — | 6 | −62.1% (6) | September 20, 2023 |
| Potts Jeannette | Chief Legal Officer | 0 | — | — | 6 | +125.3% (2) | June 17, 2026 |
| Post Leonard E | Director | 0 | — | — | 5 | +50.6% (3) | June 12, 2026 |
| Abi-Saab Walid | Chief Medical Officer | 0 | — | — | 4 | +95.6% (2) | June 30, 2026 |
| Astley-Sparke Philip | Director | 0 | — | — | 4 | +4.6% (4) | March 4, 2021 |
| Jacques Rachelle Suzanne | Director | 0 | — | — | 4 | +61.4% (2) | June 12, 2026 |
| Schaffer David | Director | 0 | — | — | 3 | +28.0% (3) | January 30, 2020 |
| Van Deventer Sander | EVP, Research & Product Dev. | 0 | — | — | 3 | +28.0% (3) | January 30, 2020 |
| Cantor Maria E | SVP, Investor Relations & Comm | 0 | — | — | 1 | +52.8% (1) | January 3, 2018 |
| Firuta Paul E | Chief Commercial Officer | 0 | — | — | 1 | +52.8% (1) | January 3, 2018 |
| Garen Jonathan | Chief Business Officer | 0 | — | — | 1 | +52.8% (1) | January 3, 2018 |
| Mcmillan Scott T. | Chief Operating Officer | 0 | — | — | 1 | +46.6% (1) | January 30, 2019 |
| O'keefe Kylie | Chief Customer & Strat Officer | 0 | — | — | 1 | — | June 12, 2026 |
| Zelenkofske Steven | Chief Medical Officer | 0 | — | — | 1 | +101.8% (1) | June 8, 2018 |
When several insiders traded Uniqure N.V.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Uniqure N.V. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 10 selling crowds, +45.8%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 4 selling | +161.3% | +29.9% | not yet |
| March 31, 2025 | 4 selling | +21.2% | +430.9% | +40.9% |
| February 29, 2024 | 3 selling | −21.8% | −2.4% | +82.0% |
| December 30, 2022 | 5 selling | −18.8% | −64.8% | −95.0% |
| January 31, 2022 | 4 selling | −5.0% | +42.3% | +27.1% |
| September 30, 2021 | 4 selling | −46.1% | −49.5% | −25.9% |
| January 29, 2021 | 3 selling | −22.0% | −37.3% | −73.1% |
| January 31, 2020 | 10 selling | +16.8% | −30.0% | −56.6% |
| January 31, 2019 | 9 selling | +61.6% | +66.7% | +46.6% |
| January 31, 2018 | 5 selling | +70.7% | +72.7% | +92.4% |